We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 19, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS
N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS
ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS
MODULATION OF THE INTERACTION BETWEEN SORLA AND GDNF-FAMILY LIGAND RECEPTORS